Effect of long-term spleen dialysate (Solcosplen) administration on plasma lipids and lipoproteins in early postmenopausal women

Gynecol Endocrinol. 1993 Jun;7(2):143-7. doi: 10.3109/09513599309152494.

Abstract

A total of 46 early postmenopausal women with elevated levels of total cholesterol, triglycerides, low-density lipid (LDL) cholesterol and lowered high density lipoprotein cholesterol (HDL) cholesterol was treated with spleen dialysate (Solcosplen), 2 x 2 tablets daily for 6 months. Serum estradiol levels rose from 42.3 +/- 15.4 pg/ml to 60.6 +/- 23.6 pg/ml and the Kupperman Index decreased significantly after 6 months of treatment. Also, a significant decrease of total cholesterol, triglycerides, LDL cholesterol, and an increase of HDL cholesterol was observed. The changes showed no correlation with the estradiol concentration and no side-effects were evident. Solcosplen is recommended as a beneficial therapy for women in the early postmenopause.

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Lipids / blood*
  • Lipoproteins / blood*
  • Longitudinal Studies
  • Luteinizing Hormone / blood
  • Middle Aged
  • Postmenopause / metabolism*
  • Progesterone / blood
  • Prolactin / blood
  • Spleen / physiology*
  • Testosterone / blood
  • Time Factors
  • Tissue Extracts / pharmacology*

Substances

  • Anticholesteremic Agents
  • Lipids
  • Lipoproteins
  • Solcosplen
  • Tissue Extracts
  • Testosterone
  • Progesterone
  • Estradiol
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone